@article{a58cdaaeb58744d4ad73064a6000ef17,
title = "Age differences in the association between sleep and Alzheimer's disease biomarkers in the EPAD cohort",
abstract = "Introduction: We aimed to determine the independent association between sleep quality and Alzheimer's disease (AD) biomarkers, and whether the associations differ with age. Methods: We included 1240 individuals aged ≥50, without dementia from the European Prevention of Alzheimer's Disease v1500.0 dataset. Linear regression was used to examine Pittsburgh Sleep Quality Index (PSQI) scores against cerebrospinal fluid (CSF) phosphorylated tau/β-amyloid ratio (p-tau/Aβ42) for the entire sample and via age tertiles. Models controlled for demographic, clinical, genetic, vascular, and neuroimaging variables. Results: For the youngest age tertile, shorter sleep duration and higher sleep efficiency were associated with greater p-tau/Aβ42 ratio. For the oldest tertile, longer sleep latency was associated with greater p-tau/Aβ42. Discussion: Differential relationships between sleep and AD pathology depend on age. Short sleep duration and sleep efficiency are relevant in middle age whereas time taken to fall asleep is more closely linked to AD biomarkers in later life. Highlights: This study shows age differences in the link between sleep and AD biomarkers. Shorter sleep was associated with greater p-tau/Aβ42 ratio in middle age. The association was independent of genetic, vascular, and neuroimaging markers of AD.",
keywords = "Alzheimer's, Aβ42, EPAD, PSQI, biomarkers, p-tau, sleep, sleep duration, sleep efficiency, sleep latency",
author = "Naismith, {Sharon L.} and Yue Leng and Palmer, {Jake R.} and Lucey, {Brendan P.}",
note = "Funding Information: Data used in the preparation of this article were obtained from the EPAD LCS data set v1500.0, doi:10.34688/epadlcs_v1500.0_19.11.29. The EPAD LCS was launched in 2015 as a public‐private partnership, led by Chief Investigator Professor Craig Ritchie, MBBS. The primary research goal of the EPAD LCS is to provide a well‐phenotyped probability‐spectrum population for developing and continuously improving disease models for Alzheimer's disease in individuals without dementia. The data is derived from three different dimensions: cognition, biomarkers, and traditional risk factors (genetic and environmental). EPAD LCS is registered at www.clinicaltrials.gov (identifier: NCT02804789). Prof Naismith and Dr Palmer were funded by an National Health and Medical Research Council (NHMRC) Boosting Dementia Fellowship (1135639). Dr Leng is supported by the National Institute on Aging (NIA) (5R00AG056598). Dr Lucey is supported by a Career Development Award from the National Institute on Aging (K76 AG054863). The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007‐2013) and EFPIA companies{\textquoteright} in‐kind contribution, and an Alzheimer's Association Grant (SG‐21‐818099‐EPAD). Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/dad2.12380",
language = "English",
volume = "14",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
number = "1",
}